Betta Pharmaceuticals Co.Ltd(300558) 3 announced on March 4 that it plans to subscribe for 200104 million pre IPO ordinary shares newly issued by Heyuan biology with its own capital of 385 million yuan at the price of 19.24 yuan per share. Meanwhile, Beiming fund, a related party of the company, plans to invest 80 million yuan to subscribe for 4158000 ordinary shares in the new pre IPO round of Heyuan biology at the same price. After the completion of this investment, the company is expected to hold 7.6% of its equity. Heyuan biology has developed a series of plant-derived new drug product pipelines such as plant-derived recombinant human serum albumin injection (hy1001), as well as a variety of recombinant cell growth factors and recombinant proteins used in various cell cultures and beauty fields.
© China Stock Market News